Evidence map›Paper›PMID 30823541›Full record

ReviewInternational journal of molecular sciences2019

Targeting the Iron-Response Elements of the mRNAs for the Alzheimer's Amyloid Precursor Protein and Ferritin to Treat Acute Lead and Manganese Neurotoxicity.

Jack T Rogers, Ning Xia, Angela Wong, Rachit Bakshi, Catherine M Cahill

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. The Azalea Hypothesis of Alzheimer Disease: A Functional Iron Deficiency Promotes Neurodegeneration.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2024
    Review
  6. Review
  7. The role of ferroptosis in neurodegenerative diseases.Frontiers in cellular neuroscience · 2024
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Iron-responsive-like elements and neurodegenerative ferroptosis.Learning & memory (Cold Spring Harbor, N.Y.) · 2020
    Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jack T RogersNeurochemistry Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA. Jack.Rogers@mgh.harvard.edu.
Ning XiaMolecular Neurobiology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA. NXIA@mgh.harvard.edu.
Angela WongNeurochemistry Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA. awfy@bu.edu.
Rachit BakshiMolecular Neurobiology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA. RBAKSHI1@mgh.harvard.edu.
Catherine M CahillNeurochemistry Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA. CCahill@helix.mgh.harvard.edu.
Massachusetts General Hospital · USHarvard University · US

Funding

Michael J. Fox Foundation for Parkinson's Research 15468Michael J. Fox Foundation for Parkinson's Research MJFF15468
6 · The paper itself

Abstract

The therapeutic value of inhibiting translation of the amyloid precursor protein (APP) offers the possibility to reduce neurotoxic amyloid formation, particularly in cases of familial Alzheimer's disease (AD) caused by APP gene duplications (Dup⁻APP) and in aging Down syndrome individuals. APP mRNA translation inhibitors such as the anticholinesterase phenserine, and high throughput screened molecules, selectively inhibited the uniquely folded iron-response element (IRE) sequences in the 5'untranslated region (5'UTR) of APP mRNA and this class of drug continues to be tested in a clinical trial as an anti-amyloid treatment for AD. By contrast, in younger age groups, APP expression is not associated with amyloidosis, instead it acts solely as a neuroprotectant while facilitating cellular ferroportin-dependent iron efflux. We have reported that the environmental metallotoxins Lead (Pb) and manganese (Mn) cause neuronal death by interfering with IRE dependent translation of APP and ferritin. The loss of these iron homeostatic neuroprotectants thereby caused an embargo of iron (Fe) export from neurons as associated with excess unstored intracellular iron and the formation of toxic reactive oxidative species (ROS). We propose that APP 5'UTR directed translation activators can be employed therapeutically to protect neurons exposed to high acute Pb and/or Mn exposure. Certainly, high potency APP translation activators, exemplified by the Food and Drug Administration (FDA) pre-approved M1 muscarinic agonist AF102B and high throughput-screened APP 5'UTR translation activators, are available for drug development to treat acute toxicity caused by Pb/Mn exposure to neurons. We conclude that APP translation activators can be predicted to prevent acute metal toxicity to neurons by a mechanism related to the 5'UTR specific yohimbine which binds and targets the canonical IRE RNA stem loop as an H-ferritin translation activator.

Indexed as

5' Untranslated RegionsAcute DiseaseAlzheimer DiseaseAmyloid beta-Protein PrecursorAnimalsDown SyndromeFerritinsHumansIronIron-Regulatory ProteinsLead Poisoning, Nervous SystemManganese PoisoningMiceMuscarinic AgonistsNeuronsProtein Biosynthesis5' Untranslated RegionsAmyloid beta-Protein PrecursorcevimelineFerritinsIronIron-Regulatory ProteinsMuscarinic AgonistsQuinuclidinesRNA, MessengerThiophenes5’untranslated regions (5’UTRs)APPferritinironLead/manganeseneurotoxicitysmall molecule modulatorstranslational control

Identifiers

PMID30823541
PMCPMC6412244
OpenAlexW2915598884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.